Reminder: Ligand to Host Analyst Day on December 4th in New York City

Reminder: Ligand to Host Analyst Day on December 4th in New York City

<0> Ligand Pharmaceuticals IncorporatedJohn L. Higgins, President and CEOJennifer Capuzelo, Investor Relations(858) 550-7584orLHADon Markley(310) 691-7100 </0>

will host an Analyst Day in New York City on Tuesday, December 4, 2012 from 10:15 a.m. to 12:00 p.m. Eastern Time (7:15 a.m. to 9:00 a.m. Pacific Time) at the Concierge Conference Center, located at 780 Third Avenue.

The program will include a discussion of the following topics:

Presentations will be given by Ligand's senior management team, and the program will also feature a presentation relating to Captisol-enabled MDCO-157 by Simona Skerjanec, Vice President, Chest Pain Care Pathway at Ligand partner The Medicines Company.

The presentations will be webcast live and can be accessed at . A replay of this webcast will be available for 90 days following the event.

Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia, and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., and The Medicines Company, among others. Please visit for more information on Captisol. For more information on Ligand, please visit .

Follow Ligand on Twitter @Ligand_LGND.

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.